Hepatitis C–associated hepatocellular carcinoma

In the United States, a large percentage of patients with hepatocellular carcinoma are serologically negative for hepatitis B. We conducted a retrospective study to determine the prevalence of hepatitis C antibody in the sera of 59 patients with hepatocellular carcinoma who were HBsAg‐negative and had no evidence of alcoholic liver disease, primary biiary cirrhosis, autoimmune hepatitis, hemochromatosis or α 1 ‐antitrypsin deficiency. Twenty patients (34%) were hepatitis C antibody‐positive and hepatitis B core antibody‐negative. All twenty patients had underlying cirrhosis, and seven (35%) had histories of transfusions. Eleven (19%) additional patients were also hepatitis C antibody‐positive but were hepatitis B core antibody‐positive as well. Twenty‐one (36%) patients were both hepatitis C antibody‐ and hepatitis B core antibody‐negative and seven (12%) were hepatitis C antibody‐negative but hepatitis B core antibody‐positive. The prevalence of hepatitis C antibody was also determined among three other population groups serving as controls and found to be 14% in 28 HbsAg‐positive patients with hepatocellular carcinoma, 44% in 76 patients with cryptogenic cirrhosis and 0.5% in 200 consecutive volunteer blood donors. We conclude that hepatitis C antibody is prevalent among patients with hepatocellular carcinoma and may therefore be a common causative agent of this disease. A significant number of patients with and without cirrhosis, negative for hepatitis C antibody and hepatitis B core antibody, remain without a discernible cause for this malignancy. Perhaps a second‐or third‐generation test will detect hepatitis C antibody in some of these patients. (H EPATOLOGY 1990;12:589–591).